Obesity-Focused Zafgen Raises Zaftig Series B
This article was originally published in The Pink Sheet Daily
Executive Summary
Three years after its launch, Zafgen emerges from stealth mode with a new CEO and another $14 million in funding.
You may also be interested in...
Zafgen Obtains $33 Million In Series C Funds To Advance Anti-Obesity Drug In Phase II
Biotech hopes to differentiate its candidate from recent obesity drug failures with better risk-to-benefit ratio, serving severely obese patients.
Zafgen Obtains $33 Million In Series C Funds To Advance Anti-Obesity Drug In Phase II
Biotech hopes to differentiate its candidate from recent obesity drug failures with better risk-to-benefit ratio, serving severely obese patients.
Top Ten Unpartnered Drugs: It's Tough To Make The Grade In CVD/Metabolics
Early-stage talent parade will be held at Windhover's Therapeutic Area Partnerships conference next week.